From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Seema Nagpal, MD
Stanford University
Palo Alto, CA, USA

1 regimens on this page
1 variants on this page


Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.


All lines of therapy

Cobimetinib & Vemurafenib


Study Dates of enrollment Evidence
Brastianos et al. 2023 (Alliance A071601) 2018-02-20 to 2020-03-31 Phase 2

Eligibility criteria

  • Histology: Papillary

Biomarker eligibility criteria

  • BRAF mutation

Targeted therapy

28-day cycles


  1. Alliance A071601: Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 Jul 13;389(2):118-126. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT03224767